SLDB
Solid Biosciences Inc. NASDAQ$7.23
Mkt Cap $563.3M
52w Low $2.41
74.7% of range
52w High $8.87
50d MA $7.33
200d MA $6.15
P/E (TTM)
-3.6x
EV/EBITDA
-2.6x
P/B
3.5x
Debt/Equity
0.1x
ROE
-58.9%
P/FCF
-3.1x
RSI (14)
—
ATR (14)
—
Beta
2.58
50d MA
$7.33
200d MA
$6.15
Avg Volume
1.3M
About
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy.…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.51 | -0.50 | +2.0% | 7.12 | +4.8% | -1.3% | +0.3% | -6.2% | +1.5% | +8.6% | +19.2% | — |
| Nov 3, 2025 | AMC | -0.42 | -0.48 | -14.3% | 5.20 | -9.4% | -15.2% | -24.4% | -18.8% | -21.9% | -20.2% | -0.2% | — |
| Aug 12, 2025 | AMC | -0.51 | -0.42 | +17.6% | 6.04 | +0.0% | +10.6% | +2.2% | +1.2% | -0.2% | -4.0% | -12.1% | — |
| May 15, 2025 | AMC | -0.53 | -0.59 | -11.3% | 2.59 | +11.6% | +6.9% | +12.0% | +13.9% | +4.2% | +11.6% | +93.8% | — |
| Mar 6, 2025 | AMC | -0.79 | -0.89 | -12.7% | 5.50 | -4.5% | -1.5% | -7.5% | +2.0% | +4.2% | -6.4% | -46.5% | — |
| Nov 6, 2024 | AMC | -0.67 | -0.79 | -17.9% | 6.14 | -0.7% | -6.0% | -4.4% | -2.4% | -10.3% | -9.4% | -17.8% | — |
| Aug 13, 2024 | AMC | -0.68 | -0.61 | +10.3% | 7.29 | +3.6% | +14.5% | +22.5% | +21.7% | +27.3% | +28.0% | +5.9% | — |
| May 15, 2024 | AMC | -0.57 | -0.64 | -12.3% | 9.69 | -0.3% | -4.0% | -7.6% | -5.9% | -12.2% | -13.4% | -18.5% | — |
| Mar 13, 2024 | AMC | -1.01 | -1.00 | +1.0% | 12.23 | +11.9% | +0.4% | +7.0% | +9.2% | +20.6% | +8.5% | -15.2% | — |
| Nov 8, 2023 | AMC | -1.20 | -1.05 | +12.5% | 2.79 | -1.4% | -23.7% | -20.8% | -22.6% | -23.7% | -2.3% | +81.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | JP Morgan | Maintains | Overweight → Overweight | — | $6.68 | $6.85 | +2.5% | +8.2% | +15.7% | +6.4% | -2.8% | +7.8% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.03 | $7.14 | +1.6% | +1.6% | -5.0% | +2.8% | +10.0% | +1.1% |
| Mar 20 | Chardan Capital | Maintains | Buy → Buy | — | $7.12 | $7.46 | +4.8% | -1.3% | +0.3% | -6.2% | +1.5% | +8.6% |
| Mar 20 | Needham | Maintains | Buy → Buy | — | $7.12 | $7.46 | +4.8% | -1.3% | +0.3% | -6.2% | +1.5% | +8.6% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $7.72 | $7.45 | -3.5% | -0.1% | -5.3% | -3.1% | +0.5% | -7.8% |
| Mar 12 | Chardan Capital | Maintains | Buy → Buy | — | $7.72 | $7.45 | -3.5% | -0.1% | -5.3% | -3.1% | +0.5% | -7.8% |
| Mar 11 | Wedbush | Maintains | Outperform → Outperform | — | $8.18 | $8.00 | -2.2% | -5.6% | -5.7% | -10.6% | -8.6% | -5.1% |
| Feb 9 | Needham | Maintains | Buy → Buy | — | $6.52 | $6.57 | +0.8% | +5.2% | +6.3% | -1.8% | -6.7% | -5.1% |
| Jan 14 | Needham | Maintains | Buy → Buy | — | $5.16 | $5.16 | +0.0% | +12.6% | +9.7% | +6.0% | +8.9% | +19.4% |
| Nov 5 | Citigroup | Maintains | Buy → Buy | — | $4.41 | $4.51 | +2.3% | -10.9% | -4.3% | -7.9% | -5.9% | +2.7% |
Recent Filings
8-K · 5.02
!!! Very High
Barinthus Biotherapeutics plc -- 8-K 5.02: Executive Change
Barinthus Biotherapeutics appointed Douglas Swirsky as Chief Financial Officer, a leadership change potentially signaling strategic financial direction for the biotech company's operations.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I need more specific information about the executive change to provide meaningful analysis. Please share details about which executive changed roles, their responsibilities, and any replacement information from the 8-K filing.
Apr 10
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Solid Biosciences' ongoing gene therapy trial shows measurable biological markers of therapeutic effect in young DMD patients, validating the treatment approach and potentially supporting future regulatory approval for this rare disease indication.
Mar 12
8-K · 1.01
! Medium
Solid Biosciences Inc. -- 8-K 1.01: Equity Issuance
Solid Biosciences raised $240 million through an equity issuance, providing capital for research and development of its gene therapy programs.
Mar 6
Data updated apr 27, 2026 1:36am
· Source: massive.com